

Phospholipid Translocation Captured in a Bifunctional Membrane Protein MprF


Danfeng Song^{1,2,†}, Haizhan Jiao^{1,2,†} and Zhenfeng Liu^{1,2,*}

¹National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, 15 Datun Road, Chaoyang District, Beijing 100101, P. R. China.

²College of Life Sciences, University of Chinese Academy of Sciences, No. 19(A) Yuquan Road, Shijingshan District, Beijing 100049, P. R. China.






[†]These authors contributed equally to this work: Danfeng Song, Haizhan Jiao.

^{*}Correspondence and requests for materials should be addressed to Zhenfeng Liu (liuzf@ibp.ac.cn).




Supplementary Figure 1. Sample preparation, cryo-EM data processing of *RfMprF(DDM)* reconstituted in nanodiscs. **a**, Purification of *RfMprF(DDM)*-nanodisc samples through gel filtration and further analysis of the peak fraction through SDS-PAGE. The experiment was repeated independently four times with similar results.

b, A representative cryo-EM image of the sample (scale bar 50 nm) and 2D class images of *RtMprF* in nanodiscs (scale bar 10 nm). A total of 2921 independent images of similar quality were collected and used for further data processing. The 2D class images shown are nine different class average results from a total of 529,371 particle images. **c**, A flow chart of data processing, 3D classification and refinement process. **d**, The Fourier Shell Correlation (FSC) curves. Black, the gold standard FSC curve between two independent half maps; red, the FSC curve between the map and structural model. **e**, Angular distribution of the major class of particles included in the final 3D reconstruction of the map. **f**, Estimation of the local resolution of the final cryo-EM map. The unit for the numbers labeled nearby the gradient color bar is Å.




Supplementary Figure 2. Sample preparation, cryo-EM data processing of *RtMprF*(GDN) reconstituted in nanodiscs. **a**, Purification of *RtMprF*(GDN)-nanodisc samples through gel filtration and further analysis of the peak fraction through SDS-PAGE. The experiment was repeated independently four times with similar results. **b**, A representative cryo-EM image of the sample. Scale bar 50 nm. A total of 2579 independent images of similar quality were collected and used for further data processing. **c**, 2D class images of *RtMprF* in nanodiscs. Scale bar 10 nm. The images shown are 30 different class average results from a total of 343,117 particle images. **d**, A flow chart of data processing, 3D classification and refinement process. **e**, The Fourier Shell Correlation (FSC) curves. Black, the gold standard FSC curve between two independent half maps; red, the FSC curve between the map and structural model. **f**, Angular distribution of the major class of particles included in the final 3D reconstruction of the map. **g**, Estimation of the local resolution of the final cryo-EM map. **h**. The local resolution map around the substrate-binding site in Cavity C with a LysPG molecule bound.




Supplementary Figure 3. Representative cryo-EM densities of different regions of *RtmprF* and the associated lipid molecules. a, Cryo-EM densities for the 14 transmembrane helices and the C-terminal synthase domain (CTD) in *RtmprF*(GDN)-nanodisc structure. All of the density features shown are from the postprocessed map with a default sharpening B-factor of -62 \AA^2 . **b,** Cryo-EM densities for the two LysPG

molecules in Cavity C and Cavity P of *RtMprF*(GDN)-nanodisc structure. **c**, Cryo-EM densities for GDN and two phosphatidylglycerol molecules (PG1 and PG3) located at the dimerization interface of *RtMprF*(GDN)-nanodisc and PG2 at the dimerization interface of *RtMprF*(DDM)-nanodisc. The *RtMprF*(DDM)-nanodisc structure contains a PG1 density highly similar to the corresponding one in *RtMprF*(GDN)-nanodisc. The binding sites of GDN and PG3 from *RtMprF*(GDN)-nanodisc partially overlaps with PG2 from *RtMprF*(DDM)-nanodisc. **d**, A zoom-in view of the local region around the head group of LysPG1 molecule in *RtMprF*(GDN)-nanodisc. The red arrows indicate the pointy features characteristic of the polar head group, distinguishing itself from the fatty acyl chains. For visualization of the local details, the cryo-EM map is contoured at 1.7 rmsd. **e**, Cryo-EM densities for the molecules in Cavity C and Cavity P of *RtMprF*(DDM)-nanodisc. In comparison, the density in Cavity P of *RtMprF*(DDM)-nanodisc is much weaker than the one in Cavity P of *RtMprF*(GDN)-nanodisc (b).




Supplementary Figure 4. Crystal structure of the synthase domain of *RfMprF*. **a**,

The cartoon model of the synthase domain. The α -helices and β -strands are colored violet and cyan, respectively. The red dash boxes define the regions belonging to GNAT folds 1 and 2. **b**, Topology of the synthase domain. The α -helices and β -strands are indicated as cylinders (violet) and arrows (cyan), respectively. GNAT folds 1 and 2 are highlighted in blue or orange background. **c**, Data collection and refinement statistics for crystal structure of *RfMprF*-SD. One crystal each was used for collecting the native and Se-Met derivative data. Values in parentheses are for highest-resolution shell.




Supplementary Figure 6. Comparison of *RfMprF* structure with those of other lipid transporters. The structures of *RfMprF*, TMEM16F [PDB: 6QP6] (<https://www.rcsb.org/structure/6QP6>), MurJ [PDB: 6NC9] (<https://www.rcsb.org/structure/6NC9>), MsbA [PDB: 5TV4] (<https://www.rcsb.org/structure/5TV4>) and Drs2p-Cdc50p [PDB: 6ROJ] (<https://www.rcsb.org/structure/6ROJ>) are shown as cartoon models. The α -helices and β -strands are colored in red and blue, respectively. TMEM16F is a calcium-activated ion channel and lipid scramblase catalyzing translocation of

phosphatidylserine. MurJ is a secondary active transporter and belongs to Multidrug/Oligosaccharidylipid/Polysaccharide (MOP) exporter superfamily, it might translocate Lipid II (the lipid-linked peptidoglycan precursor) by coupling the movement of an ion down its electrochemical gradient. MsbA is an ABC transporter and translocate Lipid A (the lipid component of bacterial lipopolysaccharides) from the inner to the outer leaflet of the inner membrane in gram negative bacteria. Drs2p-Cdc50p is a P4-type ATPase which is responsible for transporting phospholipids (such as phosphatidylserine, etc) in eukaryotic cells. Both MsbA and Drs2p-Cdc50p are primary active transporters and use ATP hydrolyzing as energy source.




Supplementary Figure 7. Alignment of the amino acid sequence of *RfMprF* with the other homologs from different species. The sequence alignment was accomplished by using Clustal Omega and presented by JalView. The α -helices and β -strands are indicated as cylinders and arrows respectively and are labeled above the sequence. The secondary elements of flippase domain are colored in rainbow colors. For the synthase domain, the α -helices and β -strands are colored in violet and cyan,

respectively. The red arrowheads indicate the conserved Glu/Asp-Arg pair serving as a barrier between Cavities C and P, while the green arrowheads label three conserved residues involved in binding the head group of LysPG. Conserved residues involved in the interactions between the flippase and synthase domains are indicated by blue arrowheads. *R. tropici*, *Rhizobium tropici*; *S. aureus*, *Staphylococcus aureus*; *B. licheniformis*, *Bacillus licheniformis*; *P. aeruginosa*, *Pseudomonas aeruginosa*; *C. perfringens*, *Clostridium perfringens* (CpMprF2); *E. faecium*, *Enterococcus faecium*; *L. monocytogenes*, *Listeria monocytogenes*.




Supplementary Figure 8. The cryo-EM densities for the lipid and detergent molecules in Cavity P of *RfMprF(GDN)*-nanodisc. a, The map contoured at $1.2 \times \sigma$ level shows three strong fatty acyl chains in Cavity P. **b**, The density feature potentially belonging to the lysyl group becomes visible when the map contour level is lowered at $0.8 \times \sigma$.



Supplementary Figure 9. Identification and quantification of LysPG co-purified with *RtMprF* protein. **a**, Mass spectrometry analysis of the lipids extracted from the purified *RtMprF* protein sample. The mass spectrometry analysis in positive and negative modes


exhibit features characteristic of LysPG molecules. **b and c**, Quantification of the LysPG co-purified with *RtMprF*(DDM) protein. The TLC plate was stained by iodine and the image shown in **b** was processed by Image J. The data extracted from the spots of the LysPG standard samples were used for linear regression of the standard curve ($Y = 54798 \times X + 20842$) as shown in **c**. By referring to the standard curve, the amount of LysPG extracted from 0.95 nmol *RtMprF* protein purified in β -DDM is estimated to be 1.227 (corresponding to ~ 1.2 LysPG per *RtMprF* monomer) as indicated by the red labels. The error bars in **c** denote the standard errors of the mean value ($n = 3$). **d**, TLC analysis of the overall total phospholipids extracted from *E. coli* cells expressing wild-type or various mutants of *RtMprF*. The TLC plate was stained by iodine and the image was processed by ImageJ. By referring to the pure lipid standard samples of cardiolipin (CL), PG, PE and LysPG loaded on the left side, the three major spots in the lipid sample extracted from cells are identified as PE, PG and LysPG, respectively. **e**, The proportion of LysPG in total phospholipids extracted from *E. coli* cells expressing wild-type or various mutants of *RtMprF*. The LysPG/total phospholipid ratio presented in the bar graphs (**e**) is calculated through dividing the LysPG spot intensity by the summed intensity of three major phospholipid spots (PE+PG+LysPG, approximating the total phospholipid quantity as the remaining ones like PS and CL are minor at low abundance) as shown on the TLC plate (**d**). The error bars in **e** indicate the standard errors of the mean values ($n = 3$). $p = 0.0583$ between WT and D234A, ns; $p = 0.00006$ between WT and Y303, ****; $p = 0.000087$ between WT and R304A, ****; $p = 0.000718$ between WT and Y307A, ***; $p = 0.000145$ between WT and E280Q, ***; $p = 0.000143$ between WT and E280K, *** (two-sided unpaired t-test between WT and various mutants). **f and g**, Quantification of the LysPG co-purified with *RtMprF*(GDN) protein. The TLC plate was stained by iodine and the image shown in **f** was processed

by ImageJ. The data extracted from the spots of LysPG standard samples were used for linear regression of the standard curve ($Y = 1202 \times X + 2197$) as shown in **g**. By referring to the standard curve, the amount of LysPG extracted from 0.89 nmol *RtMprF* protein purified in GDN is estimated to be 2.340 (corresponding to ~2.6 LysPG per *RtMprF* monomer) as indicated by the red label. The error bars in **g** denote the standard errors of the mean values (n=3). Due to the difference in the pixel size setting of raw images (3264×2448 for **b** and 1360×1024 for **f**), the intensity values of the lipid spots presented in **g** are at different scale when compared to those shown in **c**. The intensity scale difference does not affect the final results of LysPG content measurement as the standard samples of LysPG are loaded on the same plate of the lipid samples under investigation. In case that the raw image is resized proportionally, the scale of lipid spot intensity values changes accordingly, whereas the measured LysPG amount remains very close to the one derived from raw data. For **b**, **d** and **f**, each experiment was repeated independently twice (**b**) or three times (**d**, **f**) with similar results.




Supplementary Figure 10. The relationship between the synthase and the flippase domains of *RtMprF*. **a**, Superposition of the structure of FemX-aminoacyl-tRNA complex [PDB code: 4II9 (<https://www.rcsb.org/structure/4II9>)] on one monomer of *RtMprF* dimer. It is apparent that the active site in the synthase domain of *RtMprF* is distant from the LysPG-binding site in the transmembrane domain. **b**, Superposition of the structure of *B/MprF*-LYN complex [PDB code: 4V36 (<https://www.rcsb.org/structure/4V36>)] on *RtMprF* dimer. The *RtMprF* versus FemX and *B/MprF* superposition leads to root mean square deviation of α -carbon atoms at 3.1

and 2.2 Å respectively. **c**, The presence of multiple conformations of *RtMprF* dimer. Three minor classes (Classes B-D) of asymmetrical *RtMprF* dimer with conformations distinct from the major class of symmetrical dimer (Class A, used for solving the structure at 3.7 Å resolution) are shown. The cryo-EM densities are shown in the upper row, while the corresponding models are presented in the lower row. Color codes: blue, class A; magenta, class B; cyan, class C; yellow, class D. The regions covered by the solid elliptical rings are densities from the adjacent particles. In the structural models, the synthase domains exhibiting variable positions in respect to the transmembrane domain are labeled with dashed circles. The angles shown nearby are between the presumed membrane plane and the long axis of the synthase domain. **d-f**, Superposition of classes B (d), C (e) and D (f) with class A. The arrows indicate the predicted transition between the two different states.



Supplementary Figure 11. Structural model of *SaMprF* and the locations of point mutation sites found in the DAP-R *S. aureus* strains. a and b, Two different side views of *SaMprF* model with the mutation sites highlighted in colored sphere models. Color codes: orange and magenta, two gain-of-function mutations causing DAP-R; blue, the other mutations found in the DAP-R strains. c, zoom-in-view of the mutation sites clustering on TM9 in Subdomain 2. d and e, Top view (d) and sectional side view (e) of the model of daptomycin molecule docked in Cavity E of *SaMprF*. While

daptomycin is shown as stick models, *SaMprF* is presented as electrostatic potential surface model. Unit, kTe^{-1} ; color codes: red, electronegative; white, neutral; blue, electropositive. The affinity of daptomycin with *SaMprF* is -10.8 kcal/mol (estimated by the Autodock program). **f** and **g**, Clustering of numerous DAP-R-related mutation sites around the putative daptomycin-binding cavity.



Supplementary Figure 12. A peripheral lipid-like density nearby LysPG1 and at the cytoplasmic entrance of Cavity C. The *RtMprF*(GDN)-nanodisc map is contoured at $1.2 \times \sigma$ level and superposed with the stick models.

Supplementary Table 1. Cryo-EM data collection, single particle analysis and model building statistics of *RtMprF*.

	<i>RtMprF</i> (DDM)-nanodisc [EMDB-0992 (https://www.emdataresource.org/EMD-0992)] [PDB: 6LVF (https://www.rcsb.org/structure/6LVF)]	<i>RtMprF</i> (GDN)-nanodisc [EMDB-30869 (https://www.emdataresource.org/EMD-30869)] [PDB: 7DUW (https://www.rcsb.org/structure/7DUW)]
Data collection and processing		
Magnification	130,000	130,000
Voltage (kV)	200	200
Electron exposure (e ⁻ /Å)	50	50
Defocus range (μm)	-1.5 to -2.0	-1.5 to -2.0
Pixel size (Å)	1	1
Symmetry imposed	C2	C2
Initial particle images (no.)	887,196	1,232,621
Final particle images (no.)	160,417	144,479
Map resolution (Å)	3.70	2.96
FSC threshold	0.143	0.143
Map resolution range (Å)	3.2-6.0	2.2-3.8
Refinement		
initial model used (PDB code)	-	-
Model resolution (Å)	3.74	3.05
FSC threshold	0.5	0.5
Model resolution range (Å)	-	-
Map sharpening <i>B</i> factor (Å ²)	-170	-62
Model composition		
Non-hydrogen atoms	12130	13276
Protein residues	1586	1640
Water	-	2
Ligands	6 (1 LysPG, 2 PG /monomer)	12 (2 LysPG, 2 PG, 1 GDN, 1 DDM/monomer)
<i>B</i> factors (Å ²)		
Protein	67.84	52.98
Ligand	41.95	41.02
R.m.s. deviations		

Bond lengths (Å)	0.010	0.004
Bond angles (°)	1.100	0.664
Validation		
MolProbity score	1.83	1.93
Clashscore	5.89	14.13
Poor rotamers (%)	0.16	0.15
Ramachandran plot		
Favored (%)	91.38	96.01
Allowed (%)	8.62	3.99
Disallowed (%)	0	0

Supplementary Table 2. Strains, Plasmids and Primers

<i>E. coli</i> Strains used for clone screening and protein expression		
<i>Strain</i>	<i>Usage</i>	
DH5α	Clone screening	
BL21 (DE3)	Expression of the synthase domain of <i>RtMprF</i>	
C41 (DE3)	Expression of the full length <i>RtMprF</i> , <i>RtMprF</i> D234A/Y303A/R304A/E280Q/E280K/D753A mutant, <i>RtPaMprF</i>	
Plasmids used for protein expression		
<i>Plasmid</i>	<i>Gene</i>	<i>Restriction site</i>
pET21b	the synthase domain of <i>RtMprF</i> , Full length <i>RtMprF</i> , <i>RtMprF</i> D234A/Y303A/R304A/E280Q/E280K/D753A mutant, <i>RtPaMprF</i>	Nde I, Hind III
Primers used for plasmid construction		
<i>Construct</i>	<i>Primer Type</i>	<i>Primer Sequence</i>
<i>RtMprF</i>	Forward primer	5'-GATATGACCATATGTTCGAGCCCAATCGATC-3'
	Reverse primer	5'-ATGTTAAGCTTTTTCCTCACGACCCCT-3'
<i>RtMprF</i> - Synthase	Forward primer	5'-GGGAATTCCATATGGACGATGCGGTG-3'
	Reverse primer	5'-CCCAAGCTTTCGCCCCCGAT-3'
<i>RtPaMprF</i>	Forward primer	5'- CCGGCAACGAAGCGGCCGGAGCCTGTTCAGCGCGGA AGAGCTG-3'
	Reverse primer	5'- GTGGTGGTGCTCGAGTGCGGCCGCAAGCTTGCGTTT CACCAA-3'
<i>RtMprF</i> - D234A	Forward primer	5'-CACCGCATTCGCGATCGCGGCCTCG-3'
	Reverse primer	5'-CGAGGCCGCGATCGCGAATGCGGTG-3'
<i>RtMprF</i> - Y303A	Forward primer	5'-GTTCTCTGGTCTCGCGCGGTCATCTACAAC-3'
	Reverse primer	5'-GTTGTAGATGACGCGCGGAGGACCAGAGAAC-3'
<i>RtMprF</i> - R304A	Forward primer	5'-CTGGTCCTCTATGCGGTCATCTACAAC-3'
	Reverse primer	5'-GTTGTAGATGACCGCATAGAGGACCAG-3'
<i>RtMprF</i> - Y307A	Forward primer	5'-CTATCGCGTCATCGCGAACGTCATTCC-3'
	Reverse primer	5'-GGAATGACGTTTCGCGATGACGCGATAG-3'
<i>RtMprF</i> - E280Q	Forward primer	5'-CTTCGGCGTGTTCCAGACGATCATC-3'
	Reverse primer	5'-GATGATCGTCTGGAACACGCCGAAG-3'
<i>RtMprF</i> - E280K	Forward primer	5'-CTTCGGCGTGTTCAAAACGATCATCATC-3'
	Reverse primer	5'-GATGATGATCGTTTTGAACACGCCGAAG-3'
<i>RtMprF</i> - D753A	Forward primer	5'-AGGGATCCGTCGCGCTGATGCGTTTTT-3'
	Reverse primer	5'-AAAAACGCATCAGCGGACGGATCCCT-3'